SCHEMBL6474530

SCHEMBL6474530

COc1ccc(Nc2ccc(CCc3ccc(Cl)c(Cl)c3)cc2)c(C(=O)O)c1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
LMNA P02545 2/20 0.68
POLB P06746 1/20 0.68
MAPT P10636 1/20 0.68
RECQL P46063 1/20 0.67
BLM P54132 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
HPGD P15428 1/20 0.59
GFER P55789 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
AKR1C3 P42330 13/20 0.55
AKR1C2 P52895 13/20 0.55
CTSV O60911 1/20 0.51
CTSL P07711 1/20 0.51
FABP3 P05413 1/20 0.51
FABP4 P15090 1/20 0.51
PLK1 P53350 1/20 0.48
PLK3 Q9H4B4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475025 0.96 MEN1 (0.65) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL6482802 0.91 MEN1 (0.65) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL6474652 0.85 MEN1 (0.65) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL6475983 0.85 MEN1 (0.72) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL6475930 0.83 MEN1 (0.73) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL6475183 0.82 TDP1 (0.72) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL6475798 0.82 MEN1 (0.72) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL6476163 0.82 MEN1 (0.67) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL9593627 0.81 MEN1 (0.83) MEN1KMT2ALMNAPOLBMAPT
SCHEMBL6482206 0.81 MEN1 (0.66) MEN1KMT2ALMNAPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885KMT2A 4729/4885LMNA 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.